Ionis Pharmaceuticals (IONS) Non Operating Investment Income (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Non Operating Investment Income of -$10.2 million for Q2 2026, up 44.4% year-over-year from -$7.1 million in Q2 2025, and down 145.09% quarter-over-quarter from $22.6 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Non Operating Investment Income (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Non Operating Investment Income history runs 15 years deep, the most recent figure standing at -$10.2 million for Q2 2026.
- In Q2 2026, Non Operating Investment Income rose 44.4% year-over-year to -$10.2 million; the TTM figure through Jun 2026 stood at $43.1 million (up 294.44% YoY), while the FY2025 annual figure was $10.2 million, up 453.76% from the prior year.
- Non Operating Investment Income for Q2 2026 stood at -$10.2 million, down from $22.6 million in the prior quarter.
- The five-year high for Non Operating Investment Income was $29.9 million in Q3 2025, with the low at -$18.3 million in Q2 2025.
- The 5-year median for Non Operating Investment Income is -$345000.0 (2023), against an average of $582500.0.
- The sharpest annual moves came in 2024 and 2025: Non Operating Investment Income slumped 1495.03% in 2024, then jumped 3302.5% in 2025.
- Ionis Pharmaceuticals' Non Operating Investment Income stood at $3.3 million in 2022, then tumbled by 104.9% to -$161000.0 in 2023, then plunged by 1495.03% to -$2.6 million in 2024, then soared by 130.69% to $788000.0 in 2025, then slumped by 1392.13% to -$10.2 million in 2026.
- Business Quant data shows IONS's Non Operating Investment Income at -$10.2 million in Q2 2026, $22.6 million in Q1 2026, and $788000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | -10.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.18 Mn |
| Jun 30, 2026 | -10.18 Mn |
| Mar 31, 2026 | 22.58 Mn |
| Mar 31, 2026 | 22.58 Mn |
| Dec 31, 2025 | 788,000.00 |
| Dec 31, 2025 | 788,000.00 |
| Sep 30, 2025 | 29.91 Mn |
| Sep 30, 2025 | 29.91 Mn |
| Jun 30, 2025 | -18.31 Mn |
| Jun 30, 2025 | -18.31 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Dec 31, 2024 | -2.57 Mn |
| Dec 31, 2024 | -2.57 Mn |
| Sep 30, 2024 | 879,000.00 |
| Sep 30, 2024 | 879,000.00 |
| Jun 30, 2024 | -3.53 Mn |
| Jun 30, 2024 | -3.53 Mn |
| Mar 31, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.33 Mn |